Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
NCT07245992Phase 1Recruiting
- Sponsor
- Philogen
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of f8il10 in rheumatoid arthritis (RA), sponsored by Philogen. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Administered Dose, Maximum Tolerated Dose and Recommended Dose at 28 days and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
f8il10
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07245992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245992.